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BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is often accompanied 
by immune-related pathology, with an increasing occurrence of high-risk ICI-
related myocarditis. Understanding the mechanisms involved in this side effect 
could enable the development of management strategies. In mouse models, 
immune checkpoints, such as PD-1 (programmed cell death protein 1), control the 
threshold of self-antigen responses directed against cardiac TnI (troponin I). We 
aimed to identify how the immunoproteasome, the main proteolytic machinery 
in immune cells harboring 3 distinct protease activities in the LMP2 (low-
molecular-weight protein 2), LMP7 (low-molecular-weight protein 7), and MECL1 
(multicatalytic endopeptidase complex subunit 1) subunit, affects TnI-directed 
autoimmune pathology of the heart.
METHODS: TnI-directed autoimmune myocarditis (TnI-AM), a CD4+ T-cell–mediated 
disease, was induced in mice lacking all 3 immunoproteasome subunits (triple-
ip−/−) or lacking either the gene encoding LMP2 and LMP7 by immunization with a 
cardiac TnI peptide. Alternatively, before induction of TnI-AM or after establishment 
of autoimmune myocarditis, mice were treated with the immunoproteasome 
inhibitor ONX 0914. Immune parameters defining heart-specific autoimmunity were 
investigated in experimental TnI-AM and in 2 cases of ICI-related myocarditis.
RESULTS: All immunoproteasome-deficient strains showed mitigated autoimmune-
related cardiac pathology with less inflammation, lower proinflammatory and 
chemotactic cytokines, less interleukin-17 production, and reduced fibrosis 
formation. Protection from TnI-directed autoimmune heart pathology with 
improved cardiac function in LMP7−/− mice involved a changed balance between 
effector and regulatory CD4+ T cells in the spleen, with CD4+ T cells from 
LMP7−/− mice showing a higher expression of inhibitory PD-1 molecules. Blocked 
immunoproteasome proteolysis, by treatment of TLR2 (Toll-like receptor 2)–engaged 
and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)–engaged CD14+ monocytes 
with ONX 0914, diminished proinflammatory cytokine responses, thereby reducing 
the boost for the expansion of self-reactive CD4+ T cells. Correspondingly, in 
mice, ONX 0914 treatment reversed cardiac autoimmune pathology, preventing 
the induction and progression of TnI-AM when self-reactive CD4+ T cells were 
primed. The autoimmune signature during experimental TnI-AM, with high 
immunoproteasome expression, immunoglobulin G deposition, interleukin-17 
production in heart tissue, and TnI-directed humoral autoimmune responses, was 
also present in 2 cases of ICI-related myocarditis, demonstrating the activation of 
heart-specific autoimmune reactions by ICI therapy.
CONCLUSIONS: By reversing heart-specific autoimmune responses, 
immunoproteasome inhibitors applied to a mouse model demonstrate their potential 
to aid in the management of autoimmune myocarditis in humans, possibly including 
patients with ICI-related heart-specific autoimmunity.
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access article under the terms of the 
Creative Commons Attribution Non-
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The antigen-recognition signaling system is equipped with immune checkpoint molecules that regulate the threshold of antigen responses 
and prevent overactivation.1 Immune checkpoint in-
hibitors (ICIs) targeting checkpoint molecules such as 
PD-1 (programmed cell death protein 1), PD-L1 (pro-
grammed cell death ligand 1), and CTLA-4 (cytotoxic 
T-lymphocyte–associated protein 4) have revolutionized 
treatment strategies for a range of solid and hemato-
logic malignancies. Unleashing tumor-specific T cells 
in patients with cancer comes at the price of general 
activation of T cells, often resulting in autoimmunity.2 
Autoimmune-related disease as a result of ICI therapy 
often affects the skin, colon, lung, endocrine system, 
or renal system.3 Myocarditis is a less common but of-
ten fulminant and severe side effect of ICI therapy that 
may be difficult to diagnose.4 The majority of patients 
diagnosed with ICI-related myocarditis had abnormal 
ECG findings and elevated troponin levels, but most 
patients had a normal ejection fraction.4–6 Beyond case 
studies, over time, a substantial increase in the inci-
dence of ICI-related myocarditis has been documented 
in safety databases, and its high mortality rate has been 
highlighted recently.7
Preclinical mouse models have implicated the indis-
pensable role of the PD-1/PD-L1 pathway in periph-
eral tolerance of autoreactive T cells targeting cardiac 
autoantigens. Genetic deletion of PD-L1/PD-L2 (pro-
grammed cell death ligand 2), as well as treatment 
with anti–PD-L1 antibodies, transforms transient 
myocarditis into lethal disease.8 Depending on the 
genetic background, PD-1–deficient mice develop di-
lated cardiomyopathy through the generation of anti-
bodies to TnI (troponin I)8,9 or fatal lymphocytic myo-
carditis with high levels of antimyosin antibodies.10 
Observations in PD-1–deficient mice provided the first 
clear experimental demonstration of the autoimmune 
basis of dilated cardiomyopathy in mice.9 On the basis 
of these observations, our group developed a cardiac 
TnI-induced experimental autoimmune-related myo-
carditis mouse model that mirrors human disease. 
Very similar to the phenotype in PD-1–deficient mice, 
this model features cardiac inflammation and fibrotic 
scar formation leading to cardiac dysfunction and tis-
sue remodeling.11
Specific treatments for autoimmune-related heart 
disease are rare12 and because of the broad clinical 
application of ICIs, there is an urgent need for novel 
strategies for managing ICI-related myocarditis. Pro-
teasome inhibitors, which inhibit the major proteo-
lytic machinery in all cells, are in consideration for 
targeting both cancer and autoimmunity.13–15 The cat-
alytic activity of the proteasome is restricted to its 3 
β-subunits—namely, β1, β2, and β5—in the standard 
proteasome, and LMP2 (low-molecular-weight protein 
2)/β1i, MECL1 (multicatalytic endopeptidase complex 
subunit 1)/β2i, and LMP7 (low-molecular-weight pro-
tein 7)/β5i in the immune cell resident isoform, the 
immunoproteasome.16 Proteasome inhibitors, avail-
able for the treatment of multiple myeloma,17,18 tar-
get both the standard proteasome, found in all so-
matic cells, and the immunoproteasome, found in 
immune cells (eg, in multiple myeloma cells). More 
recently, selective inhibitors that specifically block the 
immunoproteasome emerged as potent compounds 
to hinder inflammation-driven carcinogenesis.13 The 
biological function of the immunoproteasome affects 
several central aspects of the immune response, such 
as major histocompatibility complex class I antigen 
presentation,19 T-cell differentiation,20 and cytokine 
production.15,21,22 Immunoproteasome proteolysis also 
controls autoimmune-related inflammation.15,21 In this 
study, we investigated how the immunoproteasome 
Clinical Perspective
What Is New?
• In 2 cases of immune checkpoint inhibitor–related 
myocarditis, evidence for a cardiac Th17 immu-
nophenotype, deposition of immunoglobulin G 
around injured cardiomyocytes, and immuno-
genicity against troponin I reflect heart-directed 
autoimmunity.
• The immunoproteasome, a multicatalytic protease 
known to induce a Th17 immunophenotype with 
disease-exacerbating potential in autoimmune 
myocarditis, is active in 2 cases of immune check-
point inhibitor–related myocarditis and induces 
cardiac inflammation in experimental TnI (troponin 
I)–induced myocarditis.
• Blockade of immunoproteasome function in TnI-
induced myocarditis decorates CD4+ T cells with 
inhibitory checkpoint molecules, suppresses pro-
inflammatory cytokine production by monocytes, 
and elevates regulatory T-cell responses, thereby 
reducing inflammatory heart tissue damage and 
improving cardiac function.
What Are the Clinical Implications?
• In PD-1 (programmed cell death protein 1)–related 
and PD-L1 (programmed cell death ligand 
1)–related immune checkpoint inhibitor–related 
myocarditis, a high-risk immune-related side effect 
of immune checkpoint inhibitor cancer immuno-
therapy, this study demonstrates heart-specific 
autoimmune response.
• By mitigating cytokine production, blocking the 
boosting of effector T cells and delivering inhibitory 
signals that increase T-cell self-tolerance, immuno-
proteasome inhibitors might aid in the manage-
ment of myocarditis with evidence of heart-specific 
autoimmune responses.
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affects TnI-directed autoimmune myocarditis (TnI-
AM). We show that selective inhibitors of the immu-
noproteasome mitigate autoimmune-related myocar-
ditis in mice, and we demonstrate the relevance of 
autoimmune-related responses for ICI-related myo-
carditis in 2 patients with cancer.
METHODS
Data Availability
All data needed to evaluate the conclusions in the article are 
present in the article or the Data Supplement. RNA-Seq raw 
data are available from Dr Meder on request. The R source 
code for RNA-Seq data analysis is available from Dr Weiner on 
request. The corresponding authors had full access to all the 
data in the study and take responsibility for its integrity and 
the data analysis.
Patients and Healthy Controls
Written and informed consent was obtained from patients 
before endomyocardial biopsies were obtained and from 
healthy donors who agreed to donate blood. The study 
was performed according to the Declaration of Helsinki. All 
procedures, as well as blood sampling, were approved by 
the local ethics committees (EA4/122/14, EA1/189/19, and 
S-240/2017).
Patient 1
A 78-year-old woman with metastatic renal cell carcinoma 
presented with edema and pain in the upper legs after receiv-
ing nivolumab (3 mg/kg, second cycle). The patient was admit-
ted to the hospital because of severe muscle pain 5 days after 
the second nivolumab treatment. No signs of acute heart fail-
ure were documented. The patient was treated with analge-
sics but not steroids. Postmortem ICI-related myocarditis was 
demonstrated.23 Serum was not available from this patient. 
Postmortem cardiac sections were evaluated microscopically.
Patient 2
A 74-year-old man with metastatic non–small-cell lung cancer 
presented with dyspnea and chest pain after receiving dur-
valumab for the second time (1.125 mg). Two years previously, 
tumor therapy included resection of the right upper lung 
lobe, chemotherapy (carboplatin AUC5 and paclitaxel), and 
radiation therapy. Durvalumab treatment had been initiated 2 
months before admission. ECG showed atrial fibrillation with 
heart rates of around 110 bpm, an initial manifestation of an 
intraventricular conduction delay with complete right bundle-
branch block and left anterior fascicular block. Elevated lev-
els of TnT (troponin T; 590 pg/mL) and creatine kinase (5119 
U/L) were detected. No evidence of pulmonary embolism or 
pneumonia was found. A coronary angiogram showed stable 
coronary artery disease and no signs of progression in com-
parison to an angiogram from 2016. Serial echocardiograms 
and cardiac magnetic resonance imaging revealed normal 
left ventricular systolic function, and the magnetic resonance 
imaging showed no signs of edema. Endomyocardial biopsies 
obtained from the left ventricle revealed ICI-related myocardi-
tis. After treatment with glucocorticoids (160 mg/d predniso-
lone), the heart failure symptoms improved.
Animals and Experimental Autoimmune 
Myocarditis
This study was carried out in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
Animals of the German Animal Welfare Act, which is based on 
the directive of the European Parliament and of the Council 
on the Protection of Animals Used for Scientific Purposes 
(directive 2010/63/EU). Local state authorities in Karlsruhe 
and Berlin approved all procedures involving the use and 
care of animals (German Animal Protection Code: G-161/14, 
G-0054/18, and G-0103/18). To induce TnI-AM, mice were 
immunized subcutaneously with a solution of 150 µg murine 
cardiac TnI peptide HARVDKVDEERYDVEAKVTKNITEIADLT 
QKIYDLRGKFKRPTLRRVRIS (Peptide Specialty Laboratories, 
Heidelberg, Germany) diluted in complete Freund’s adjuvant, 
which was supplemented with 5 mg/mL of Mycobacterium 
tuberculosis H37Ra (Sigma, St Louis, MO).
Statistics
Statistical analysis of the data was performed using GraphPad 
Prism version 7.00 for Windows (GraphPad Software, La 
Jolla, CA). All data are plotted as individual points. Normal 
distribution of the control group was tested using the 
D’Agostino-Pearson normality test. Data summaries are given 
as mean±SEM. If data were strongly skewed, they were plot-
ted as median±interquartile range. Paired or unpaired t tests 
were used for 2-group comparisons. If samples had unequal 
variances (determined by an F test), an unpaired t test with 
the Welch correction was used. If the data were skewed, the 
nonparametric Mann-Whitney test was performed to com-
pare ranks. All tests used were 2-tailed. For multiple group 
comparison with repeated measurements, 2-way analysis of 
variance was performed followed by a multiple comparison 
test. The threshold of significance for all tests was set at 0.05.
RESULTS
Absence of the 3 Catalytic Subunits of 
the Immunoproteasome Abrogates TnI-
AM in Mice
For induction of experimental autoimmune myocar-
ditis (TnI-AM) comprising leukocyte recruitment, and 
fibrotic scar formation (Figure  1A through 1C), mice 
received several inoculations of an immunogenic cardi-
ac TnI peptide24 in conjunction with complete Freund’s 
adjuvant supplemented with Mycobacterium tubercu-
losis H37Ra. As a first step toward defining the influ-
ence of immunoproteasome-mediated proteolysis on 
the induction of autoimmune-related myocarditis, TnI-
AM was investigated in mice lacking all 3 catalytically 
active subunits of the immunoproteasome—LMP2, 
LMP7, and MECL1, called triple-ip−/−—and in wild-type 
(wt) controls. TnI-AM was induced to a variable extent 
in 77% of TnI peptide–immunized wt mice, whereas 
none of the triple-ip−/− mice demonstrated significant 
signs of infiltration (Figure 1A and 1B). Consistently, wt 
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controls showed collagen deposition, whereas triple-
ip−/− mice had greatly attenuated infiltration and a sig-
nificant reduction of fibrotic scar formation (Figure 1A 
and 1C). Control mice that received complete Freund’s 
adjuvant injections but no TnI peptide revealed no his-
tologic or phenotypic signs of TnI-AM, as expected 
(Figure IA in the Data Supplement). Corresponding 
to substantially decreased inflammatory injury of the 
heart tissue, the formation of TnI-directed immuno-
globulin G (IgG) antibodies was significantly reduced 
in triple-ip−/− mice (Figure 1D).
Members of the chemokine superfamily are cru-
cial for leukocyte recruitment into heart tissue during 
TnI-AM,25 and we found elevated levels of expression 
for the mononuclear cell–attracting molecules CCL2, 
CCL3, CCL4, and CCL5 in inflamed mouse hearts 
Figure 1. Genetic ablation of LMP2 (low-molecular-weight protein 2), LMP7 (low-molecular-weight protein 7), and MECL1 (multicatalytic endopepti-
dase complex subunit 1) in A/J mice with attenuated TnI (troponin I) autoimmune myocarditis.
Mice lacking LMP2, LMP7, and MECL1 (triple-ip−/−) and wild-type (wt) controls (13 per group) were immunized with TnI peptide on days 0, 7, and 14. Mice were 
killed after 28 days. A, Representative photographs of mouse hearts. Paraffin-embedded heart tissue sections were prepared and stained using hematoxylin-
eosin (HE) or acid fuchsin orange G (Afog). Representative images are shown for each group. Percentage of inflamed area (B) and fibrosis (C) was scored by 2 
experienced readers. D, TnI antibody titers were determined by enzyme-linked immunosorbent assay. E, Heart tissue was homogenized and RNA was extracted 
for quantitative polymerase chain reaction analysis of the indicated chemokines, their respective receptor molecules, and proinflammatory molecules interleukin 
(IL)–1β, IL-6, and tumor necrosis factor (TNF)–α. Relative mRNA levels were normalized to the housekeeping gene L32 and mRNA induction was normalized to 
data obtained with complete Freund’s adjuvant–immunized wt mice (n=4; Figure I in the Data Supplement). For normally distributed data, data summary is plot-
ted as mean±SEM and a t test was performed (with Welch correction if variances were significantly different). For skewed data (TnI antibodies, CCR1, IL-1β), the 
median±interquartile range was plotted and a Mann-Whitney test was performed. P values are indicated in each graph.
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(Figure 1E). The expression of the chemokine receptor 
molecules CCR1, CCR2, and CCR5 was increased con-
sistently. In line with diminished inflammatory dam-
age found in triple-ip−/− mice during TnI-AM, hearts 
from triple-ip−/− mice had lower expression of the CC 
chemokines, as well as their respective receptor mol-
ecules, in comparison with wt controls (Figure 1E). In 
line with this, expression of the proinflammatory cyto-
kines interleukin (IL)–1β, IL-6, and tumor necrosis fac-
tor (TNF)–α was substantially lower in triple-ip−/− mice 
and found to be within the range of nonpeptide im-
munized mice (Figure 1E).
Deletion of LMP2 or LMP7 Mitigates TnI-
AM
Triple-ip−/− mice experience little to no TnI-AM, so we 
analyzed single knock outs of LMP2 and LMP7 to de-
termine whether the lack of only 1 of the 3 genes is 
sufficient to confer the observed protection from TnI-
AM. We therefore induced TnI-AM in mice lacking the 
gene encoding the LMP2 or the LMP7 subunit. As with 
the triple-ip−/− mice, TnI-AM was less severe in both 
LMP2−/− and LMP7−/− mice. Ablation of either LMP2 or 
LMP7 resulted in profound reduction of heart tissue in-
flammation and fibrosis formation (Figure 2). The effect 
Figure 2. Deletion of LMP2 (low-molecular-weight protein 2) or LMP7 (low-molecular-weight protein 7) mitigated the inflammatory damage of the 
heart in TnI (troponin I)–directed autoimmune myocarditis.
LMP2−/− as well as LMP7−/− mice and their respective controls were immunized according to the protocol described for mice lacking LMP2, LMP7, and MECL1 
(triple-ip−/−) and killed after 28 days. Photographs of mouse hearts and heart tissue sections stained with hematoxylin-eosin (HE) or acid fuchsin orange G (Afog) 
representative for TnI (troponin I)–immunized LMP2−/− mice (A), LMP7−/− mice (B), and their littermate controls are depicted. HE-stained and Afog-stained heart 
tissue sections were scored microscopically by 2 experienced readers. Percentage of inflamed area (C) and fibrosis (D) was assessed (n=12 for LMP2+/+, LMP2−/−, 
and LMP7+/+; n=13 for LMP7−/−). Normally distributed data (LMP7−/− and respective wild-type [wt] controls) were plotted as mean±SEM and a t test was performed 
(with Welch correction if variances were significantly different). Skewed data (LMP2−/− and respective wt controls) were plotted as median±interquartile range and 
a Mann-Whitney test was performed. P values are indicated in each graph.
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of the immunoproteasome on cardiac function during 
TnI-AM was assessed by echocardiography exemplarily 
in LMP7−/− mice and their littermate controls (Table 1). 
In comparison with age- and sex-matched naive con-
trols, during TnI-AM, both the stroke volume and the 
left ventricular ejection fraction were reduced in wt 
mice. In contrast, LMP7−/− mice showed no relevant de-
terioration of either cardiac function measure during 
TnI-AM. As another surrogate measure of systolic func-
tion, we determined the fractional area change. Dur-
ing TnI-AM, we found a significantly decreased frac-
tional area change in wt mice, whereas LMP7−/− mice 
were protected from this TnI-AM–mediated reduction 
(Table 1). Together with the low level of inflammation 
observed, the preservation of stroke volume, left ven-
tricular ejection fraction, and fractional area change af-
ter induction of TnI-AM in LMP7−/− mice are indicators 
of a lack of disease-induced cardiac functional deterio-
ration in this strain.
Next, we addressed the question of whether a dys-
functional immunoproteasome in LMP2−/− and LMP7−/− 
mice influences the abundance of chemotactic molecules 
and their respective receptors during TnI-AM. In line with 
diminished inflammation and fibrosis formation, the ex-
pression levels of CCL chemokines were reduced in TnI-
immunized LMP2−/− and LMP7−/− mice compared with wt 
controls (Figure 3A), and this was accompanied by low 
levels of CCR1, CCR2, and CCR5 (Figure 3B). The deletion 
of each single immunoproteasome subunit suppressed 
the production of proinflammatory cytokines in heart tis-
sue as well. We found a significant decrease of IL-1β, IL-
6, and TNF-α in both LMP2−/− and LMP7−/− mouse hearts 
(Figure 3C). Because autoimmune-related pathology in 
experimental TnI-AM and in humans involves the activ-
ity of CD4+ T cells,24,26,27 we also investigated surrogates 
for CD4+ T-cell effector function in inflamed heart tissue. 
TnI-AM resulted in robust upregulation of hallmark cy-
tokines produced by either Th1 cells (interferon-γ, IL-2) 
or Th17 cells (IL-17). Genetic deletion of either LMP2 or 
LMP7 reduced the expression of interferon-γ, IL-2, and 
IL-17 in the heart (Figure 3D).
Together with decreased infiltration and lower chemo-
kine and proinflammatory cytokine production in cardiac 
tissue, the reduction of T-cell cytokines was indicative of 
diminished effector T-cell responses in mice with a dys-
functional immunoproteasome. Therefore, we investigat-
ed whether the immunoproteasome indeed affects the 
activation status of T cells. Focusing on acute TnI-AM in 
LMP7−/− mice, we analyzed the expression of CD44 and 
CD62L on the surface of splenic T cells by flow cytom-
etry (Figure 4A and 4B). The abundance of CD44 and of 
CD62L on CD8+ T cells was the same in controls and dur-
ing TnI-AM for both the wt and LMP7−/− mice (Figure 4A). 
The presence of LMP7 had no effect on the levels of the 
T-cell L-selectin CD62L in naive CD4+ T cells, but during 
TnI-AM the expression of CD62L was significantly higher 
in LMP7−/− mice. Cell surface expression of the CD44 an-
tigen, which is a cell surface glycoprotein characteristic of 
an activated effector or memory T cell, was reduced on 
CD4+ T cells in LMP7−/− mice, particularly during TnI-AM 
(Figure 4B). Altogether, these data pointed to lower CD4+ 
T-cell activation in LMP7−/− mice on TnI immunization. 
Because checkpoint molecules such as PD-1 regulate the 
threshold of antigen responses against the heart mus-
cle,8–10 we investigated whether the immunoproteasome 
influences PD-1 expression on T cells. We found that sple-
nocytes obtained from LMP7−/− mice during TnI-AM had 
higher PD-1 expression on both CD8+ and CD4+ T cells 
(Figure 4C and 4D). Higher mRNA expression of PD-1 in 
splenocytes from LMP7−/− mice confirmed elevated deco-
ration of CD4+ T cells with PD-1 molecules (Figure 4E). 
mRNA expression levels of both CD25 and FoxP3 (fork-
head box protein P3), which define the CD4+ T-cell subset 
of inducible regulatory T cells (Tregs), were increased in 
LMP7−/− mice during TnI-AM (Figure 4E). Together with 
unaltered overall CD4 mRNA expression levels during TnI-
AM, these data indicate pronounced CD4+ T-cell differen-
tiation into Tregs in LMP7−/− mice.
Table 1. Analysis of Cardiac Function in LMP7−/− Mice During Acute TnI-AM
Parameter
Controls TnI-AM
Wild Type LMP7−/− Wild Type LMP7−/−
Heart rate, bpm 395.1±10.5 407.7±9.8 466.9±7.4* 490.1±14.2*
Trace left ventricular ejection fraction, % 57.6±2.5 59.4±0.7 47.4±2.1* 52.1±2.4
Fractional area change, % 49.1±1.1 49.6±1.2 36.8±2.1*† 48.2±2.6
Stroke volume, µL 21.7±1.2 19.2±0.8 15.6±1.4* 18.0±1.2
Cardiac output, mL/min 8.4±0.6 7.9±0.5 7.3±1.5 8.8±0.7
Left ventricle internal diameter at diastole, mm 3.5±0.1 3.4±0.1 3.29±0.04 3.25±0.06
Left ventricle internal diameter at systole, mm 2.4±0.06 2.3±0.05 2.4±0.06 2.4±0.11
Cardiac function was assessed by echocardiography (Vevo 3100) during the acute state of TnI-AM 28 days after the initial TnI immunization in LMP7−/− mice and in 
wild-type littermate controls (7 in each group). As a control, cardiac function was assessed in age- and sex-matched naive control mice (10 A/J–wild-type and 9 A/J–LMP7−/− 
mice). Female controls were 9 to 10 weeks old, which is equivalent to the age of mice at the acute stage of TnI-AM. Data are mean±SEM. Two-way analysis of variance 
was performed, followed by a Tukey multiple comparison test. AM indicates autoimmune myocarditis; LMP7−/−, low-molecular-weight protein 7; and TnI, troponin I. 
*Significant changes between naive controls and TnI-AM mice of the same strain. 
†Significant change between wild-type and LMP7−/− mice during TnI-AM. 
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Blockade of the Immunoproteasome by 
ONX 0914 Diminishes TnI-AM
Because deletion of either LMP7 or LMP2 was suffi-
cient to prevent disease development during TnI-AM 
(Figures 2 and 3), we investigated whether ONX 0914, 
a potent third-generation inhibitor selective for the 
immunoproteasome,15 influences TnI-AM. The mice 
received ONX 0914 a total of 3 times per week for 4 
weeks, starting 1 day before TnI immunization (Fig-
ure 5A). As indicated by an upward shift of the respective 
protein band in Western blot analysis of splenic homog-
enates, ONX 0914 blocked LMP7 nearly completely and 
LMP2 partially (Figure IIIA in the Data Supplement). In 
Figure 3. Deletion of LMP2 (low-molecular-weight protein 2) or of LMP7 (low-molecular-weight protein 7) suppressed chemokine and cytokine 
production in the inflamed heart.
Heart tissue obtained from LMP2−/− mice, LMP7−/− mice, and their respective littermate controls during the acute phase of TnI (troponin I)–directed autoimmune 
myocarditis (TnI-AM) was homogenized (n=12 for LMP2+/+, LMP2−/−, and LMP7
+/+; n=13 for LMP7−/−). RNA was extracted for quantitative real-time polymerase 
chain reaction analysis of chemokines (A), chemokine receptors (B), proinflammatory cytokines (C), and hallmark T-cell cytokines (D). The induction of mRNA was 
normalized to LMP2+/+ or LMP7+/+ no-peptide/complete Freund’s adjuvant–treated mice (n=5). Normally distributed data (LMP7−/− and respective controls: CCL3, 
CCL4, CCL5, CCR1, CCR2, CCR5, tumor necrosis factor [TNF]–α, interferon [IFN]–γ, and interleukin [IL]–17; and LMP2−/− and respective control: CCL5) were plot-
ted as mean±SEM and a t test was performed. Skewed data (LMP2−/− and respective controls: CCL3, CCL4, CCR1, CCR2, CCR5, IL-1β, IL-6, TNF-α, IFN-γ, IL-2, and 
IL-17; and LMP7−/− and respective controls: IL-1β, IL-2, and IL-6) was plotted as median±interquartile range and a Mann-Whitney test was performed. P values are 
indicated in each graph. wt indicates wild-type.
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Figure 4. Deletion of LMP7 (low-molecular-weight protein 7) shaped CD4+ T-cell responses during TnI (troponin I)–directed autoimmune myocarditis 
(TnI-AM).
LMP7−/− mice and their respective controls were immunized according to the protocol described and killed after 28 days (7 wild-type [wt]; 6 LMP7−/− mice) for isola-
tion of splenocytes. In a separate experiment, splenocytes were isolated from sex-matched naive LMP7−/− mice and wt controls (5 per group). T cells were defined 
as CD3+ and further distinguished as CD3+CD4+ or CD3+CD8+. Cellular surface expression of CD44, CD62-L (A and B), and PD-1 (programmed cell death protein 
1; C and D) was determined by flow cytometry. In addition to median fluorescence intensity (MFI), the relative frequency of PD-1–expressing T cells was deter-
mined, and representative contour plots are depicted showing the abundance of PD-1–expressing CD8+ and CD4+ T cells in wt and LMP7−/− mice during TnI-AM. 
PD-1 expression was not affected in naive LMP7−/− mice in comparison to naive wt controls (data not shown). Normally distributed data (CD44 on CD8+ T cells: na-
ive and TnI-AM; CD44 and CD62L on CD4+ T cells: TnI-AM; percent PD-1+ CD4+ T cells: TnI-AM) were plotted as mean±SEM and a t test was performed. Skewed 
data (CD62L on naive CD8+ and CD4+ T cells; CD44 on naive CD4+ T cells; percent PD-1+ CD8+ T cells: TnI-AM; MFI PD-1 on CD8+ and CD4+ T cells: TnI-AM) was 
plotted as median±interquartile range and a Mann-Whitney test was performed. P values are indicated in each graph. E, mRNA expression levels of the indicated 
target genes (PD-1, CD4, CD25, FoxP3 [forkhead box protein P3]) were determined in splenic tissue during TnI-AM and normalized to respective nonpeptide, 
complete Freund’s adjuvant–treated, age- and sex-matched controls (2 wt mice; 2 LMP7−/− mice) using the 2−ΔΔCt method. Data are plotted as mean±SEM and a t 
test was performed (for FoxP3, a Welch correction was performed).
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line with our findings in all immunoproteasome-deficient 
mouse strains, analysis of heart tissue during TnI-AM re-
vealed distinct differences between ONX 0914-treated 
and vehicle-treated mice. Histologic staining of heart 
tissue (Figure  5B) and subsequent quantitative scoring 
of the inflamed area as well as of the collagen content 
(Figure  5C and 5D) demonstrated myocardial injury in 
vehicle-treated A/J mice; in contrast, only moderate in-
filtration and fibrosis formation were observed after in-
hibitor treatment. To obtain more information on how 
ONX 0914 mitigates TnI-AM, infiltrating immune cells of 
hearts from vehicle-treated and ONX 0914-treated mice 
were analyzed quantitatively by flow cytometry. Vehicle-
treated A/J mice demonstrated a high abundance of 
CD45+/CD11bhigh myeloid cells on TnI immunization and 
only a minor infiltration of lymphoid cells. ONX 0914 re-
duced this infiltration of CD45+/CD11bhigh myeloid cells 
significantly. Further differentiation of these myeloid cells 
revealed that ONX 0914 inhibited infiltration of Ly6Chigh 
inflammatory monocytes significantly. The abundance of 
Ly6Clow monocytes and macrophages was lower under 
the influence of ONX 0914 (Figure IIIB and IIIC in the 
Data Supplement, with the gating strategy for flow cy-
tometry of cardiac inflammatory cells being presented in 
Figure 5. Inhibition of the immunoproteasome by ONX 0914 diminished TnI (troponin I)–directed autoimmune myocarditis (TnI-AM).
A, Wild-type (wt) A/J mice (n=20) were divided into 2 groups that received either vehicle or ONX 0914 a total of 3 times a week starting 1 day before the first TnI 
immunization (n=10 for vehicle and n=10 for ONX 0914). On days 7 and 14, mice received a second and third immunization, respectively. Mice were killed 25 and 
26 days after the first immunization (equal distribution of both treatment groups). B, On induction of TnI-AM, hearts were removed. Representative micrographs 
of hematoxylin-eosin (HE)–stained or acid fuchsin orange G (Afog)–stained heart tissue sections are demonstrated. Heart tissue slides were scored microscopically 
for inflammation (C) and fibrosis (D) as described. Data summary is plotted as mean±SEM and a t test with Welch correction was performed. P values are indicated 
in each graph. E, Wild-type A/J mice (n=24) were immunized with TnI peptide and immunization was repeated after 7 and 14 days. Once autoimmune injury of 
the heart was evident, all immunized mice were divided into 2 groups that received either vehicle or ONX 0914 a total of 3 times a week starting on day 14 (equal 
distribution of both treatment groups). Mice were killed on day 42. F, Representative micrographs of HE-stained or Afog-stained heart tissue sections are demon-
strated. Heart tissue slides were microscopically scored for inflammation (G) and fibrosis (H) as described. Data summary is plotted as median±interquartile range 
and a Mann-Whitney test was performed. P values are indicated in each graph.
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Figure II in the Data Supplement). We also tested wheth-
er ONX 0914 affects cardiac disease once immune cells 
have already infiltrated the heart. Therefore, TnI-AM was 
induced in A/J mice and ONX 0914 treatment was post-
poned until after the third immunization on day 14. The 
noncontrol mice received ONX 0914 a total of 3 times a 
week and mice were killed after 42 days (Figure 5E). His-
tologic investigation of mouse hearts demonstrated that 
ONX 0914 had a beneficial effect on the level of inflam-
mation, even after TnI-triggered autoimmune injury of 
the heart had already taken place. After 42 days, we de-
tected mitigation of perimyocardial tissue injury in ONX 
0914-treated mice, as indicated by low-grade inflamma-
tion and reduced collagen deposition (Figure 5F through 
5H). To investigate the influence of ONX 0914 treatment, 
initiated on day 14, on cardiac function, we performed 
echocardiography in the same groups on days 28 and 
42. At the acute stage of TnI myocarditis on day 28, ONX 
0914 treatment improved cardiac function, as reflected 
by higher stroke volume. Further supportive evidence 
of functional benefit achieved in the ONX 0914 group 
came from improvement of the fractional area change 
and the peak mitral annular systolic and early diastolic 
velocity, the latter resulting in a lower ratio between early 
mitral inflow velocity and mitral annular early diastolic 
velocity (E/e′). Left ventricular ejection fraction showed a 
similar but insignificant improvement in the ONX 0914 
group. At the advanced stage on day 42, in comparison 
with day 28, cardiac infiltration and fibrosis formation 
was less severe and echocardiographic parameters were 
similar in vehicle-treated and ONX 0914-treated mice 
(Table 2). The naive control groups presented in Table 1 
and in Table I in the Data Supplement had a stroke vol-
ume similar to that of mice at an advanced state of TnI-
AM (Table 2).
ONX 0914 Reduces TLR (Toll-Like 
Receptor)–Triggered Cytokine Production 
in Human Monocytes
Monocytes produce inflammatory and chemotactic cy-
tokines, and, in myocarditis, secreted molecules such 
as IL-6 activate expansion of self-reactive CD4+ T cells 
and their differentiation into Th17 effector cells. These 
cells, in turn, have detrimental effects on autoimmune-
related myocarditis.27–29 Moreover, monocytes are the 
main producers of CCL chemokines required for the 
development of TnI-AM.25 Therefore, we investigated 
whether immunoproteasome inhibitors influence cy-
tokine production by monocytes, as suggested by our 
results. Human CD14+ blood monocytes isolated from 
healthy donors showed a robust induction of CCL3, 
CCL4, CXCL2, IL-1β, TNF-α, and IL-6 production when 
activated with synthetic ligands of TLR2, TLR7/8, and 
TLR4, which are involved in monocyte activation, lead-
ing to heart-specific autoimmunity.27,30 Blockade of the 
immunoproteasome by ONX 0914 greatly inhibited the 
transcriptional activity of these chemokines/cytokines, 
with the most effective suppression of cytokine expres-
sion being observed for TLR2 (Figure 6).
Table 2. Effect of ONX 0914 on Cardiac Function During TnI-AM
Parameter
Day 28 Day 42
Vehicle ONX 0914 Vehicle ONX 0914
Heart rate, bpm 429±13 401±20 418±16 452±18
Trace left ventricular ejection fraction, % 59.7±2.9 66.5±3.4 67.1±1.5 66.7±3.0
Fractional area change, % 51.0±3.1 63.4±3.4* 49.7±2.6 55.3±2.3
MV s´, mm/s 17.3±0.9 23.0±1.9* 25.7±2.0 25.4±1.3
Stroke volume, µL 14.2±2.3 21.0±2.0* 20.8±1.3 18.5±1.7
Left ventricle internal diameter at diastole, mm 2.8±0.1 3.2±0.2 3.2±0.1 3.3±0.1
Left ventricle internal diameter at systole, mm 2.0±0.1 2.1±0.1 2.1±0.1 2.1±0.1
MV E, mm/s† 695.3±33.1 728.0±81.2 744.0±50.7 651.8±36.8
MV e´, mm/s† 14.1±1.3 22.6±2.0* 30.3±3.3 32.4±2.7
MV E/e´† 51.0±3.7 33.1±1.9‖ 23.6±1.3 21.6±3.5
MV ejection time, ms† 55.5±2.0 51.8±1.5 44.7±1.8 46.6±1.1
MVdecel, ms† 20.7±2.5 25.5±1.5 18.8±1.0 17.0±1.2
Isovolumic relaxation time, ms† 18.8±0.9 17.9±1.5 14.2±0.6 15.7±0.6
Mice were treated with ONX 0914 starting 14 days after the initial TnI peptide immunization and underwent echocardiography (Vevo 3100) to monitor left 
ventricular systolic and diastolic function on days 28 and 42 (all mice immunized with TnI peptide on day 0, 7, and 14 had elevated serum TnT levels on day 28: 7 
vehicle, 7 ONX 0914). Data are mean±SEM. Unpaired t tests were conducted and ONX 0914 treatment had no significant effect on cardiac function (Table I in the 
Data Supplement). Peak mitral valve (MV) systole (s´) and early diastole (e´) velocity were determined by tissue Doppler imaging. Isovolumic relaxation time, MV 
ejection time, MV deceleration time (MVdecel), and early MV inflow (E) velocity were determined by pulse-wave Doppler at MV. AM indicates autoimmune myocarditis; 
E/e′, ratio between early mitral inflow velocity and mitral annular early diastolic velocity; TnI, troponin I; and TnT, troponin T.
*Significant changes between vehicle-treated and ONX 0914–treated mice on day 28. 
†Measure to assess diastolic function of the left ventricle.
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Evidence for Heart-Specific Autoimmune 
Reactions in Cases of ICI-Related 
Myocarditis
To investigate the overall activation of heart-directed au-
toimmunity in ICI-related myocarditis, heart tissue from 
a patient with PD-1 inhibitor–related myocarditis (patient 
1) and a patient with PD-1L inhibitor–related myocarditis 
(patient 2) were investigated by immunohistochemistry. 
Patchy lesions with lymphocytic (CD3) and monocytic/
macrophage (CD68) infiltration showed greatly increased 
expression of both LMP2 and LMP7 subunits, indicating 
Figure 6. ONX 0914 reduced TLR (Toll-like receptor)–induced cytokine production in human monocytes.
Monocytes from 7 to 11 healthy donors were treated with ONX 0914 or dimethyl sulfoxide (DMSO) before stimulation with (A) TLR2 agonist Pam3CK4 (a 
synthetic triacylated lipopeptide), (B) the TLR7 agonist resiquimod R848 (an imidazoquinoline), or (C) the TLR4 agonist lipopolysaccharide (LPS). After 4 hours, che-
motactic (left diagram) and proinflammatory cytokine expression (right diagram) was determined for the indicated genes by TaqMan quantitative polymerase chain 
reaction. Data points represent the mRNA expression of the respective gene for each donor in TLR2-, TLR7/8-, and TLR4-activated cells. The expression of mRNA 
was normalized to the mRNA level in cells that were not treated with the respective TLR agonist for both DMSO-treated and ONX-0914–treated cells, respectively 
(2−ΔΔCt method). Paired t tests were performed on 2−ΔΔCt values between TLR-activated DMSO-treated and ONX-0914–treated cells and P values are depicted. HPRT 
indicates hypoxanthine-guanine phosphoribosyltransferase; IL, interleukin; and TNF, tumor necrosis factor.
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high immunoproteasome activity in ICI-related myocardi-
tis (Figure 7A through 7C), similar to TnI myocarditis in 
mice (Figure IV in the Data Supplement). We examined 
these 2 cases of ICI-related myocarditis for signs of heart-
specific autoimmune reactions. Immunohistochemical 
analysis revealed diffuse deposition of IgG in inflamed foci 
(Figure 7A and 7B), whereas nonaffected heart tissue was 
negative for IgG. To confirm the presence of an autoim-
mune reaction against the heart, we examined the Th17 
immunophenotype in ICI-related myocarditis, and found 
IL-17+ cells in the heart (Figure 7A and 7B). Gene set en-
richment analysis of RNA-Seq data, which we obtained 
from endomyocardial biopsies of patient 2, in comparison 
with 2 control samples, revealed a significant upregula-
tion of specific inflammatory modules such as the major 
histocompatibility complex–TLR7-TLR8 cluster or of genes 
involved in antigen presentation, cell adhesion, and B- 
and T-cell activation (Figure 7C and Figure V in the Data 
Supplement). To compare the inflammatory gene signa-
ture of this ICI-related myocarditis case with autoimmune 
myocarditis in mice, on the basis of the inflammatory sig-
nature that we detected in TnI-AM, we defined a gene 
set comprising markers for immunoproteasome expres-
sion, TLR-mediated activation of monocytes, chemokine 
and cytokine responses, as well as T- and B-cell activation 
(Table II in the Data Supplement). We found a significant 
enrichment of this autoimmunity gene set in endomyo-
cardial biopsies from patient 2 (Figure 7C and 7D), sug-
gesting that similar inflammatory pathways are involved 
in both ICI-related myocarditis and experimental TnI-AM 
in mice. More information on the autoimmune pheno-
type in ICI-related myocarditis was obtained from analysis 
of the humoral immune response in patient 2. Serum ex-
hibited high-titer IgG activity of 1:160 against human TnI, 
as demonstrated by enzyme-linked immunosorbent assay 
and confirmed by Western blotting (lane 2, Figure 7E). 
We also investigated whether this TnI-directed humoral 
immune response in ICI-related myocarditis is specific 
for the immunogenic epitope that is known to induce 
autoimmune-mediated infiltration of immune cells to the 
heart in the mouse model of TnI-AM.24 We performed 
Western blotting with serum from patient 2 of a 50mer 
TnI peptide harboring the myocarditogenic TnI epitope 
VDKVDEERYDVEAKVTKN and found specific detection of 
this immunogenic peptide (lane 1, Figure 7E). This finding 
defines TnI as an autoantigen in this case of ICI-related 
myocarditis and supports the applicability of the TnI-AM 
mouse model to investigate autoimmune-related myo-
carditis in ICI therapy. Altogether, our data show that, in 
these 2 patients, heart-specific autoimmune reactions are 
active in ICI-related myocarditis.
DISCUSSION
Advances in cancer immunotherapy using ICI to treat 
metastatic disease have improved survival tremendously. 
Blockade of central immune checkpoints such as the 
PD-1:PD-1L pathway unleashes tumor-specific T cells 
but also attenuates signals regulating T-cell tolerance, 
leading to the activation of self-reactive T-cell effec-
tor function and triggering injury of heart tissue.1,2,8–10 
Autoimmune-related myocarditis has emerged as a 
high-risk adverse event in ICI therapy.5,7 In this study, 
we focused on the pathophysiologic functions of the 
immunoproteasome in an experimental model of TnI-
AM. As summarized in Figure  8, we found that the 
immunoproteasome stimulates the activation and ex-
pansion of self-reactive CD4+ T cells and suppresses in-
hibitory signals. In monocytes, the protease regulates 
TLR signaling, leading to high expression of proinflam-
matory cytokines, thereby steering CD4+ T-cell differen-
tiation toward Th17 and Th1 effector cells. These effec-
tors reduce the Treg pool and stimulate autoantibody 
production. These processes ultimately result in severe 
inflammatory heart tissue damage, fibrotic scar forma-
tion, and cardiac dysfunction. Elimination of immuno-
proteasome–protease activity by ONX 0914 elevates 
the threshold of cardiac autoantigen responses, reca-
librating the balance of the immune system and avoid-
ing overactivation, thereby reducing cardiac injury and 
maintaining function (Figure 8).
Regulation of Autoimmune-Related 
T-Cell Effector Function by the 
Immunoproteasome
CD4+ T cells are the main trigger of autoimmune-re-
lated myocarditis.24,33 Activation of self-reactive CD4+ T 
cells targeting cardiac proteins such as TnI24 or myosin33 
requires antigen presentation by dendritic cells (DCs), 
and occurs only when DCs are stimulated through 
TLR-mediated signaling.33 Self-antigens released from 
cardiomyocyte-derived proteins on tissue damage are 
sensed by DCs through TLRs, and the resulting pheno-
typic and functional changes in DCs trigger their migra-
tion and facilitate antigen presentation. The immuno-
proteasome is a necessary component of the signaling 
pathways between the TLRs and MyD88 (myeloid dif-
ferentiation primary response 88), which integrates 
their signals.15,34 Elimination of immunoproteasome 
activity compromises TLR–MyD88 pathways,35 result-
ing in impaired antigen presentation, thereby limiting 
autoimmune-related T-cell effector activity and attenu-
ating cardiac injury, as reported in this study in mice 
with immunoproteasome deficiency or blocked immu-
noproteasome activity.
Beyond antigen presentation by DCs, immuno-
proteasome-dependent biological processes involve 
CD4+ T-cell activation, proliferation,36 and exhaus-
tion.35 LMP7−/− mice undergoing TnI-AM have higher 
CD62L and lower CD44 expression on CD4+ T cells 
than wt control mice, which indicates a lower state 
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Figure 7. Immunoproteasome expression, immunoglobulin G (IgG) deposits, and Th17 cells indicated heart-directed autoimmune activity in cases of 
immune checkpoint inhibitor–related myocarditis.
A, Postmortem diagnosis of a fatal case of nivolumab-related myocarditis (patient 1).23 B, Endomyocardial biopsies from durvalumab-related myocarditis (patient 
2). For patient 2, 2 different foci from the same biopsy are depicted. Staining with hematoxylin-eosin (HE) shows acute lymphocytic infiltration. The inflammatory 
infiltrate included CD3-positive T cells and CD68-positive macrophages. Myocardial tissue stained for the immunoproteasome subunits LMP2 (low-molecular-
weight protein 2) and LMP7 (low-molecular-weight protein 7) indicated high immunoproteasome expression. Heart sections stained with antihuman IgG illustrate 
deposition of IgG. The blue arrows in sections stained with antibody against interleukin (IL)–17 point toward Th17 cell infiltration. C, Gene set enrichment analysis 
results of RNA-Seq data from endomyocardial biopsies of patient 2 (for information regarding overall differential gene expression, refer to Table III in the Data 
Supplement). Each bar corresponds to a single gene module from the tmode package.31 The gene set “autoimmunity” was operator-defined based on the inflam-
matory signature detected in the mouse model of TnI (troponin I)–directed autoimmune myocarditis (TnI-AM; Table II in the Data Supplement). The length of the 
bar represents effect size (enrichment strength as area under the curve [AUC]). The color intensity corresponds to P value; adjusted P values are shown below the 
color-coded image plot. With the exception of the inflammation module, all selected modules have a P<0.01 and AUC>0.75. (Continued )
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of T-cell activation in LMP7−/− mice, similar to findings 
for CD8+ T cells during lymphocytic choriomeningitis 
virus infection.37 PD-1 delivers inhibitory signals spe-
cifically to CD4+ T cells that regulate T-cell tolerance 
and protects from autoimmune-related myocarditis.38 
Therefore, increased PD-1 levels, as reported here 
for LMP7−/− CD4+ T cells during TnI-AM, corroborate 
the pathophysiologic relevance of low T-cell effec-
tor activity as the trigger of mitigated pathology in 
immunoproteasome-deficient mice. In both mice and 
patients with autoimmune-related myocarditis and di-
lated cardiomyopathy, specific CD4+ T-cell subsets, in 
particular Th17 cells, contribute to cardiac remodel-
ing processes.27,29 In 2 cases of ICI-related myocarditis 
studied by us, we found IL-17–producing T cells in 
the heart as well, providing evidence for heart-spe-
cific immune responses in these cases of ICI cancer 
immunotherapy. The immunoproteasome pushes 
CD4+ T-cell differentiation toward higher Th17 and 
Th1 expansion.20 In immunoproteasome-deficient 
strains, we demonstrate reduced Th17 (IL-17) and 
Th1 (interferon-γ) hallmark cytokines during TnI-AM, 
indicating diminished self-reactive CD4+ T-cell effector 
function on elimination of the immunoproteasome.
Monocytes are the main producers of proinflam-
matory cytokines, which govern expansion of autore-
active CD4+ T cells and their differentiation into Th17 
cells.27 Induction of Th17 cells can also occur when 
memory CD4+ T cells encounter TLR-activated mono-
cytes.39 Immunoproteasome inhibitors, however, ef-
ficiently block the production of proinflammatory 
cytokines, particularly in TLR2- and TLR7/8-activated 
monocytes. This finding is important because both 
TLR2- and TLR7/8-activated monocytes can trigger 
a Th17 immunophenotype in patients with autoim-
mune myocarditis.27,30 Similar to human myocarditis 
or  dilated cardiomyopathy,27 in the presence of el-
evated proinflammatory cytokines, decreased Tregs 
characterize the Th17 immunophenotype in auto-
immune TnI-related myocarditis. In immunoprotea-
some-deficient mice, however, lower IL-6 and IL-1β 
production reshapes CD4+ T-cell differentiation to-
ward elevated Treg abundance during TnI-AM. CD4+ 
Tregs mitigate autoimmune-related cardiac disease.27 
In line with high PD-1 expression and elevated Treg 
abundance in LMP7−/− mice during TnI-AM, PD-1 and 
its ligands also promote the development and func-
tion of Tregs, and thereby protect against potentially 
pathogenic self-reactive effector T cells.1 Altogether, 
reduced T-cell activation, elevated T-cell tolerance, 
and limitation of Th17 immunophenotype are benefi-
cial aspects of reducing immunoproteasome function 
in autoimmune-related myocarditis. It remains uncer-
tain to what extent protection from TnI-AM in immu-
noproteasome-deficient or ONX 0914-treated mice 
can be attributed to an altered effector CD4+ T-cell 
repertoire. A number of different mechanisms have 
been described to explain the function of the immu-
noproteasome in effector CD4+ T cells in the context 
of different diseases.14,20 What these mechanisms 
have in common is that impaired immunoproteasome 
function blocks autoimmune tissue damage.15,21
Function of the Immunoproteasome 
in Innate Myeloid Cells and Effect on 
Myocarditis
CD11b+ monocytes/macrophages are the major 
heart-infiltrating immune cells during TnI-AM and 
are central for mediating tissue damage and fibrotic 
scarring.40 Results from experimental and clinical trials 
indicate that chemokines are crucial for the patho-
genesis leading to heart failure. By binding to their 
receptors CCR2 and CCR5, CCL2 and CCL3 stimulate 
inflammatory heart tissue injury in TnI-AM, and abro-
gation of CCR2 and CCL2 in monocytes/macrophages 
reduces inflammatory tissue damage in the heart.25,41 
The expression of monocyte/macrophage-attracting 
cytokines, as well as their receptor molecules, dropped 
significantly in the inflamed hearts from triple-ip−/−, 
LMP2−/−, and LMP7−/− mice during TnI-AM. As shown 
by reduced infiltration of myeloid immune cells un-
der the influence of ONX 0914, we propose that in 
mice lacking significant immunoproteasome function, 
suppressed chemokine production by monocytes is 
another beneficial aspect mediating protection from 
cardiac inflammation. Infiltrating monocytes/macro-
phages are a major source of proinflammatory cyto-
kines, such as IL-1β, IL-6, and TNF-α, in the inflamed 
mouse heart.42 Consistent with previous reports,15,21,22 
production of IL-6, IL-1β, and TNF-α was suppressed 
during TnI-AM in immunoproteasome-deficient mice 
Figure 7 Continued. Red indicates the fraction of genes significantly upregulated in the patient sample in comparison to 2 controls, with the P value corrected for 
multiple testing (q<0.05) and absolute log2 fold change >0.5. D, For the autoimmunity gene set, receiver operator characteristic (ROC) is shown. Of 28 genes from 
the autoimmunity gene set, 17 were present in the analyzed data. Vertical axis and the gray bar next to the curve represents the list of genes ordered by the P value 
of the comparison of cardiac gene transcription between patient 2 and controls. Horizontal dashes indicate genes, which were included in the autoimmunity gene set 
and their position in the list of transcripts. Horizontal axis shows the fraction of the genes in the gene set. AUC represents the enrichment strength (effect size for the 
gene set enrichment). Evidence plots for all other gene modules are shown in Figure V in the Data Supplement. E, Immunoblot with the 50mer TnI peptide harboring 
the immunogenic TnI epitope VDKVDEERYDVEAKVTKN (lane 1) and human TnI (lane 2) as antigen stained by Ponceau S stain (left image). Alternatively, for the same 
immunoblot, serum from patient 2 was used as a primary antibody, and antigen-bound serum antibodies were visualized by chemiluminescence detection of bound 
antihuman secondary antibody (right image). *The 50mer TnI peptide harboring the immunogenic TnI epitope VDKVDEERYDVEAKVTKN was loaded in lane 1. adj. 
indicates adjusted; BAFF, B-cell activating factor; CXCL2, C-X-C motif chemokine ligand; MHC, major histocompatibility complex; PD-1, programmed cell death protein 
1; PD-L1, programmed cell death ligand 1; pept, peptide; ROR-γt, RAR-related orphan receptor C-γt; and TLR, Toll-like receptor.
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and in TLR2-, TLR7/8-, and TLR4-activated human 
monocytes lacking immunoproteasome activity. Local 
secretion of the cytokines IL-1 and TNF by infiltrating 
inflammatory cells in the heart promotes the induc-
tion of autoimmune disease,43 and there is evidence 
that high IL-6, IL-1β, or TNF-α production can con-
tribute to cardiodepressive pathology.27,44 Therefore, 
lower cytokine production in mice lacking immuno-
proteasome activity is of high biological relevance for 
the development of heart failure, and is consistent 
with a low degree of fibrosis and improved cardiac 
performance in LMP7−/− or ONX 0914-treated mice 
during TnI-AM.
Immunoproteasome Inhibitors as a 
Strategy for Autoimmune-Related 
Myocarditis
Bortezomib and carfilzomib, which are licensed for the 
treatment of multiple myeloma,18 primarily target the 
highly abundant β5 subunit of the cardiac proteasome 
complex,45 and thereby disrupt protein homeostasis in 
cardiomyocytes, resulting in cell death,46 thus constitut-
ing a risk for the development of cardiac dysfunction. 
Compounds selectively targeting the immunoprotea-
some may provide a useful alternative strategy regard-
ing the maintenance of cardiac proteostasis. ONX 0914 
Figure 8. The multifaceted function of the immunoproteasome in cardiac autoimmune-related disease.
A, On activation, T cells express checkpoint molecules such as PD-1 (programmed cell death protein 1). PD-1 limits potentially aberrant effector function of self-
reactive T cells by increasing the threshold needed for activation.1 B, Cancer immunotherapy with inhibitors of the PD-1 pathway reactivates T cells, occasionally 
with adverse effects on the heart.4,7,32 In 2 cases of immune checkpoint inhibitor (ICI)–related myocarditis, high cardiac expression of the immunoproteasome, 
cardiac immunoglobulin G (IgG) deposits, evidence for TnI (troponin I)–directed autoimmunity, and Th17 immunophenotype demonstrate heart-specific autoim-
munity. Experimental data from animal models showing myocarditis or dilated cardiomyopathy through the generation of cardiac autoantibodies (TnI, myosin) in 
PD-1–deficient mice by the Honjo group8,9 indicate an autoimmune etiology of ICI-related myocarditis in some patients. C, In mice, an immunogenic TnI peptide 
can trigger myocarditis,11,24 and this TnI peptide was found to be immunogenic in a patient with ICI-related myocarditis. During the onset of cardiac autoimmu-
nity in mice, the immunoproteasome controls CD4+ T-cell activation and expression of checkpoint molecules and stimulates the production of chemotactic and 
proinflammatory cytokines (eg, in monocytes), the later governing CD4+ T-cell differentiation into Th17 and Th1 cells.27 Subsequently, inflammatory monocytes 
migrate into the heart, resulting in tissue damage with functional impairment. D, Inhibition of the immunoproteasome by ONX 0914 mitigates the autoimmune-
related inflammatory response in TnI myocarditis in mice and minimizes heart muscle damage, leading to improved cardiac performance. §Findings of this study. 
ab indicates antibody; APC, antigen-presenting cell; TCR; T-cell receptor; Th1, CD4+ Th1 cell; Th17, CD4+ Th17 cell; and Treg, CD4+ regulatory T cell.
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injected into mice before or after immunization with the 
TnI peptide at a dose blocking both LMP7 and LMP215 
was successful at preventing the development of TnI-
AM, verifying the role of the immunoproteasome for ac-
tivation and expansion of self-reactive T cells. A previous 
study illustrated the beneficial outcome of the immu-
noproteasome inhibitor ONX 0914 during severe virus-
induced myocarditis, revealing no adverse effect on the 
formation of an antiviral adaptive and memory immune 
response.22 The immunoproteasome has a minor influ-
ence on the control of cardiotropic pathogens,22,47,48 and 
this is consistent with reports for other pathogens.36 
Another putative concern is the degree of subunit se-
lectivity after long-term application of compounds that, 
like ONX 0914, bind irreversibly to subunits of the im-
munoproteasome.15 If long-term treatment with an im-
munoproteasome inhibitor is found to be necessary, the 
use of a reversible immunoproteasome inhibitor with 
improved subunit selectivity would be preferable.35
Heart-Specific Immune Responses in ICI-
Related Myocarditis
Our data unequivocally demonstrate that immunopro-
teasome inhibitors in a mouse model attenuate autoim-
mune-related myocarditis. We need further research to 
define the role of immunoproteasome-dependent pro-
teolysis in human patients with cancer with ICI-related 
myocarditis. Nevertheless, on the basis of our experimen-
tal mouse data, immunoproteasome inhibitors could be 
suitable principally for the treatment of patients with ICI-
related autoimmune myocarditis who have evidence of 
heart-specific autoimmunity. In 2 patients with ICI-related 
myocarditis, we showed the activation of heart-specific 
autoimmune responses. Similar to autoimmune-related 
myocarditis in mice, we found elevated cardiac immuno-
proteasome expression and a Th17 immunophenotype. 
Moreover, in the patient with cancer with ICI-related 
myocarditis, in whom we conducted RNA sequencing of 
endomyocardial biopsies, we found significant enrich-
ment of a known gene set that compromised, among 
other inflammatory markers, hallmark genes of the 
T- and B-cell response, known to be relevant for experi-
mental autoimmune myocarditis in mice. Preclinical data 
showing myocarditis or dilated cardiomyopathy through 
the generation of cardiac autoantibodies (TnI or myosin) 
in PD-1–deficient mice8,9 provide further supportive evi-
dence for the autoimmune etiology of ICI-related myo-
carditis. In our cases of ICI-related myocarditis, we de-
tected IgG deposits in cardiac inflammatory foci, which 
corresponds to IgG deposits surrounding cardiomyocytes 
in PD1−/− mouse hearts,8 later identified to be specific for 
TnI.9 Somewhat in contrast with our findings, in 2 previ-
ously reported cases of ICI-related myocarditis, such IgG 
deposits were absent. Nevertheless, in the same patients, 
common T-cell receptor sequences in infiltrates from the 
heart and tumor raise the possibility for heart-specific 
autoimmunity in these cases as well.4 Further supporting 
evidence for heart-specific immunity in ICI-related myo-
carditis comes from another PD-1 inhibitor–related myo-
carditis case with detection of preexisting heart-directed 
autoimmunity.49 It is noteworthy in this context that, 
because of the loss of inhibition by PD-1 molecules, ef-
fector T cells can be reactivated by ICI.2 The detection of 
autoimmune activity against the immunogenic TnI pep-
tide in a case of ICI-related myocarditis, as shown here, 
provides additional proof for heart-specific autoimmu-
nity, being active or activated at least in this case of ICI-
related myocarditis. Together with shared inflammatory 
transcriptome signatures in ICI-related myocarditis and 
experimental TnI-AM, this validates the TnI-AM mouse 
model by showing it reflects human pathology. In the 
presented case of ICI-related myocarditis, TnI-directed 
autoantibodies indeed targeted the same immunogenic 
epitope that we used to trigger autoimmune myocardi-
tis in mice.24 Although preclinical work and experimen-
tal evidence define a link among the physiologic role of 
immunoproteasome function, PD-1/PD-1L expression, 
TnI-directed cardiac autoimmunity, and ICI-related myo-
carditis, further studies should combine murine cancer 
models with ICI therapy to elucidate the proposed au-
toimmune pathogenesis of ICI-related myocarditis in a 
more physiologically relevant context.
The immunoproteasome regulates processes that 
balance autoimmune responses in the heart. We have 
shown that immunoproteasome inhibitors can be used 
therapeutically in a mouse model of TnI-directed car-
diac autoimmunity and thus show the potential for 
further exploration in models of ICI-related myocarditis 
and potentially also in patients with evidence of heart-
specific autoimmunity.
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